Apretude 30 mg Tablets or 600 mg/3ml Injection
PDF Leaflet Revision Date: 5 February 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Pre-exposure prophylaxis (PrEP) for HIV-1 infection.
Dosage (summary)
30 mg orally once daily for 28 days, followed by 600 mg IM every 2 months.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; potential fetal exposure.
Key Drug Interactions
- Rifampicin
- Rifapentine
- Phenytoin
- Carbamazepine
Contraindications
- Hypersensitivity to cabotegravir
- Positive HIV-1 status
Common side effects
- Injection site reactions
- Headache
- Diarrhoea
Counselling Points
- Adhere to dosing schedule
- Monitor for signs of hypersensitivity
- Regular HIV testing required
Serious warnings
- Not always effective in preventing HIV-1
- Potential for resistance if HIV-1 acquired during treatment
Important Disclaimer
The Apretude 30 mg Tablets or 600 mg/3ml Injection professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
